NJ High Court Won't Disturb Novartis Bone Drug Win

Law360, New York (November 7, 2012, 6:35 PM EST) -- The New Jersey Supreme Court has declined to hear a challenge to judgments for Novartis Pharmaceuticals Corp. in the first bellwether trial in consolidated litigation over claims the drugmaker's bone cancer drugs Aredia and Zometa caused jaw deterioration.

The high court denied certification for the case, in which the state's appeals division had backed key lower-court rulings against plaintiff Jane Bessemer's direct-to-consumer advertising claims and failure-to-warn allegations. The certification order was filed Oct. 25 and publicly released earlier this month.

In June, a three-judge appeals panel...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.